The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
HONG KONG, June 27, 2026 /PRNewswire/ -- Chuangxinzhong, a precision marketing subsidiary of Yeahka (9923.HK), has become the top-ranked partner by model consumption among...
LISHUI, China, June 27, 2026 /PRNewswire/ -- Farmmi, Inc. (NASDAQ: FAMI) (the "Company"), an agriculture products supplier in China and a logistics and supply...
CHONGQING, China, June 27, 2026 /PRNewswire/ -- Life Pulse of Yangtze, an international co-production by Jiangsu Broadcasting Corporation, Chongqing Broadcasting Group, and A+E Networks,...
